Heterocyclic compounds as sting antagonists

Abstract

COMPOUNDS OF FORMULA 1:1: AND THEIR USE AS STING ANTAGONISTS, FOR EXAMPLE, FOR THE TREATMENT OF A DISEASE SELECTED FROM THE GROUP CONSISTING OF: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), INTERFERONOPATHIES (MONOGENIC AND DIGENIC) (INCLUDING CHILDHOOD-ONSET STING-ASSOCIATED VASCULOPATHY (SAVI), AICARDI-GOUTIÈRES SYNDROME (AGS), COPA SYNDROME, AND FAMILIAL LUPUS PERNIOSIS), TYPE 1 INTERFERONOPATHIES WITH MUTATIONS IN THE DNASE2 OR ATAD3A GENES, AGE-RELATED MACULAR DEGENERATION (AMD), RETINOPATHY, GLAUCOMA, AMYOTROPHIC LATERAL SCLEROSIS (ALS), DIABETES, OBESITY, INFLAMMATORY BOWEL DISEASE (IBD), Chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSC), dermatomyositis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), acute or chronic liver failure (ACLF), interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), aging / muscle disorders, septicemia, heart failure RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS.